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Introduction: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in
the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound
healing problems, gastrointestinal perforation, proteinuria and hypertension.
Case presentation: We present the case of a 65-year old Asian man with synovial metastasis of the knee who
experienced intraarticular hemorrhage after bevacizumab treatment. He presented with monoarthritis of the left
knee.
Conclusion: Bevacizumab-related hemorrhage can cause serious morbidity and unusual sites of hemorrhage may
be seen.
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Colorectal cancer is the third most common cancer in
both men and women. should be: "It is also the third
most common cause of cancer-related deaths [1]. Sur-
vival rates have increased from 41% to 66% between
1950 and 2000. The main reason for this improvement
is the use of effective cytotoxic therapies such as oxali-
platin and irinotecan. Targeted therapies beginning with
bevacizumab in 2004 have improved the overall survival
of patients with metastatic colorectal cancer up to two
years [2].
Bevacizumab is the first angiogenesis inhibitor that
binds and inactivates all isoforms of vascular endothelial
growth factor (VEGF). It has some specific side effects
including severe bleeding, wound healing problems,
gastrointestinal perforation, proteinuria and hyperten-
sion. Hemorrhages are usually related to metastasis or
primary tumor itself. No case of intraarticular bleeding
due to bevacizumab has been reported previously in the
literature. We report the case of a man with knee joint* Correspondence: mukreminuysal@yahoo.com
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reproduction in any medium, provided the ormetastasis from colon adenocarcinoma who experienced
intraarticular hemorrhage subsequent to bevacizumab
treatment.Case presentation
A 65-year-old Asian man was diagnosed with stage 3
colon cancer and treated with adjuvant fluorouracil and
leucoverin. After six years he had a relapse with brain
and lung metastates. After cranial metastasectomy, he
was treated with full brain radiotherapy. Chemotherapy
with capecitabine and bevacizumab was started (capeci-
tabine 1000mg/m² twice a day one to 14 days, bevacizu-
mab 7.5mg/kg on the first day, every 21 days).
Oxaliplatin- or irinotecan-based chemotherapy could
not be given due to his poor Eastern Cooperative Oncol-
ogy Group (ECOG) performance score. The lung lesion
was resected after partial response to six cycles of
chemotherapy. He discontinued therapy and did not
come to control visits. After three months he presented
to our clinic with weight loss, weakness and pain in his
left knee. His carcinoembryonic antigen was increased
and positron emission tomography-computed tomog-
raphy (PET- CT) revealed multiple liver, lung and bonetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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at the same dose and frequency as he had received pre-
viously. After the first course of this regimen, he pre-
sented with monoarthritis in the left knee. Physical
examination revealed tenderness, swelling and reduced
mobility. Laboratory studies revealed a hemoglobin value
of 10.2g/dL; white blood count of 7800/mm3 (Normal
ratio<10,800) and C-reactive protein of 0.45mg/dl (Nor-
mal ratio <0.4mg/dL). The left knee was aspirated and
yielded hemorrhagic fluid. He had no history of a trau-
matic event or use of warfarin, heparin or acetylsalicylic
acid. He had no history of hemorrhagic diathesis. Co-
agulation parameters were normal. A magnetic reson-
ance image (MRI) revealed synovial metastasis of the
knee (Figure 1). Cytologic examination was not done
and he refused to have an arthroscopic biopsy. Bevacizu-
mab was stopped and palliative radiotherapy (3000cGy
in 10 fractions) to the left knee region was administered
to relieve the symptoms.
Discussion
This is the first case of bevacizumab-related intraarticu-
lar bleeding reported in the literature. Intraarticular
hemorrhage was associated with the synovial metastasis
of the left knee. Synovial metastasis is a rare entity; it is
usually seen in solid tumors. Only a few reported cases
of metastatic adenocarcinoma to the synovium can be
found in the literature [3-6]. The differential diagnoses
of monoarthritis in a patient with cancer include inflam-
matory diseases such as gout, avascular necrosis and
septic arthritis which could be complications of chemo-
therapy. Various rheumatic disorders may also be seen
[7]. In this patient bleeding stopped after discontinuation
of bevacizumab and he had palliative radiation therapy
to the left knee. Surgical procedures such as palliative
synovectomy are also possible. If these measures fail and
joint instability causes significant pain external or in-
ternal fixation may be considered.Figure 1 Magnetic resonance image showing knee joint and synovial
sagittal plane images, there is a lesion in the femur medial condyle epiphy
and shows edematous changes in the near bone. In the same sequences,
at this location there is another poor hyperintense lesion (bone and synovBevacizumab is the first angiogenesis inhibitor that
binds and inactivates all isoforms of VEGF. The most
common side effects are hypertension, proteinuria, epi-
staxis, gastrointestinal symptoms and poor wound heal-
ing. Infrequent serious adverse events include
gastrointestinal perforation, arterial thrombotic events
and hemorrhage [8]. Severe and life-threatening (Grade
3 or 4) bleeding has occurred among three to four per-
cent of the patients who received bevacizumab. Hemor-
rhages are usually related to metastasis or the primary
tumor itself. Bleeding events usually appear as epistaxis,
gastrointestinal bleeding, hemoptysis, vaginal bleeding
and intracranial hemorrhage and occur five times more
often in patients treated with bevacizumab [8]. The most
common form of hemorrhage is mild epistaxis that lasts
less than five minutes and usually resolves without medi-
cation. These bleedings do not require discontinuation
of bevacizumab therapy [9].
The mechanism underlying bevacizumab-related
bleeding is not fully understood. It is probably associated
with the inhibition of VEGF signaling. VEGF stimulates
endothelial cell proliferation, promotes endothelial cell
survival and helps to maintain the vascular integrity. In-
hibition of VEGF can reduce the regenerative capacity of
endothelial cells [10]. However, endothelial cell defects
alone cannot explain the life-threatening hemorrhages in
patients receiving anti-VEGF therapy; damage of the
major vessel wall by tumor erosion, necrosis, cavitation
and other pathologic conditions may have a role [10].Conclusions
Bevacizumab-related hemorrhage can cause serious
morbidity even mortality. Unusual sites of hemorrhage
may be seen. Clinicians should examine the symptoms
of monoarthritis carefully in patients treated with beva-
cizumab and should not continue the therapy until they
rule out intraarticular hemorrhage.metastasis. In short TI reversion proton density (STIR PD) sequences;
seal-metaphyseal line which has a peripheral hyperintense signal
there is an increase of synovial fluid in the suprapatellar pouch and
ial metastasis).
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Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
VEGF: Vascular endothelial growth factor; PET-CT: Positron emission
tomography-computed tomography.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This manuscript was not supported with any financial or other relationships.
Authors’ contributions
MU and HSC designed the work; MU wrote the paper. MU, HSC, SSG, BS, MO
and HB followed up with the patient. MU and HSC reviewed the article. All
authors read and approved the final manuscript.
Received: 28 October 2011 Accepted: 11 May 2012
Published: 9 July 2012
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics.
CA Cancer J Clin 2009, 59:225–249.
2. Wagner AD, Arnold D, Grothey AAG, Haerting J, Unverzagt S:
Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane
Database Syst Rev 2009, (3):CD005293.
3. Beckers C, Foidart J, Thiry A, Malaise MG: Synovial metastases from colonic
cancer presenting as arthritis of the knee. Characterization by 18FDG
PET scan. Rev Med Liege 2002, 57:467–474.
4. Griener B, Müller-Färber J: Patellar metastasis of colon carcinoma. A rarity
in differential diagnosis of acute knee pain. Case report. Unfallchirurg
2001, 104:778–781.
5. Currall VA: Dixon John H: Synovial metastasis: an unusual cause of pain
after total knee arthroplasty. J Arthroplasty 2008, 23:631–636.
6. Devis P, Iwannik D, Aikens C: Metastatic adenocarcinoma presenting as
monoarticular arthritis of the knee. AJR Am J Roentgenol 2005,
184:S107–S109.
7. Capovilla M, Durlach A, Fourati E, Beucher AB, Eschard JP, Dehoux E,
Le Noach J, Cucherousset J: Chronic monoarthritis and previous history of
cancer: think about synovial metastasis. Clin Rheumatol 2007, 26:60–63.
8. Avastin, Avastin (prescribing information): Avastin (prescribing information).
South San Francisco, Calif: Genentech Inc; 2011. http://www.avastin.com/
avastin/hcp/index.html.
9. Saif MW, Mehra R: Incidence and management of bevacizumab-related
toxicities in colorectal cancer. Expert Opin Drug Saf 2006, 5:553–566.
10. Kamba T, McDonald DM: Mechanisms of adverse effects of anti VEGF
theraphy for cancer. Br J Cancer 2007, 96:1788–1795.
doi:10.1186/1752-1947-6-188
Cite this article as: Uysal et al.: Intraarticular hemorrhage due to
bevacizumab in a patient with metastatic colorectal cancer:
a case report. Journal of Medical Case Reports 2012 6:188.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
